EnglishРусский中文EspañolDeutsch
Independent world news

Alzheimer's pill AR1001 slows decline by 31% in phase 3 trial

An experimental pill that relaxes blood vessels and raises blood flow to the brain slowed cognitive decline by 31% in a late-stage Alzheimer's trial, according to topline results from its developer, the South Korean company AriBio.

Alzheimer's pill AR1001 slows decline by 31% in phase 3 trial
Photo: Jensflorian / Wikimedia Commons, CC BY-SA 4.0

The drug, AR1001, was tested in a phase 3 trial of 604 patients with early Alzheimer's disease who were not taking other medicines for the condition. In that group, cognitive decline was almost a third slower than in patients given a placebo, the results show.

The trial ran in 13 countries, including the United Kingdom, and was presented at the Clinical Trials on Alzheimer's Disease conference in Boston. The data are topline figures from the company and have not yet been published in full or peer reviewed.

The result comes with a caveat. In a wider group that also included patients taking other Alzheimer's symptom drugs, the effect did not reach statistical significance.

Some media describe AR1001 as a pill that mimics Viagra. The comparison is loose: both work on blood vessels, but AR1001 is a separate drug, and specialists warned people against using Viagra to treat Alzheimer's themselves.

UK dementia charities called the findings encouraging but said further trials and an independent scientific and regulatory assessment are needed. Earlier observational studies linked erectile dysfunction drugs to a lower risk of Alzheimer's, but they could not establish cause and effect.

Alzheimer's pillAR1001AriBioAlzheimer's phase 3 trialcognitive decline
More in Science